Prevalence of Diabetic Retinopathy Within the Hospital Eye Service in Four Local Health Boards in Wales. Ceri Richards 1 , Andrew Crowder 1 , Gavin Bhakta 1 , Stephen Luzio 2 , Rebecca Thomas 2 , David Owens 2 . 1.Diabetic Retinopathy Screening Service for Wales. 2.Diabetes Research Group, Swansea University
Introduction The Diabetic Retinopathy Screening Service for Wales (DRSSW) is a community based mobile service, providing annual screening for all persons with diabetes in Wales over the age of 12 years. Exclusions from screening include: 1) Temporary: persons under the care of a hospital eye service (HES) or dissenters, 2) Permanent: persons confirmed medically unfit to undergo screening and/or blind (in both eyes).
DIABETIC RETINOPATHY SCREENING SERVICE for WALES • Standardised digital cameras (Canon DGi) • Standardised image capture (2x45 o retinal images) North Wales • Centralised grading and Screening Office administration Mobile screening • Single standard grading teams protocol Clinic details Clinic Emails details Images Grading Stations Admin Stations Emails Mobile screening teams West Wales Screening Office Mobile screening teams South Wales Referrals Screening Office and from GP’s Grading Centre
The DRSSW service user population across Wales
Introduction Previous research has shown that the prevalence of diabetic retinopathy (DR) within the DRSSW to be 32.4% and referable DR (RDR) to be 5% (Thomas et. al., 2104) However, this may be an underestimate of the true prevalence of DR, especially sight-threatening DR (STDR) in Wales. This is because the research did not include those who had not been screened by DRSSW and were under the care of the Hospital Eye Service (HES). Referable DR is defined as Pre-proliferative DR, Proliferative DR with or without exudative maculopathy and exudative maculopathy with background DR.
Methods All persons with diabetes in Wales are notified to the DRSSW by their general practitioner. In May 2012 there were 182,195 persons with diabetes registered with the DRSSW. Of these, 18,729 (10.3%) persons were temporarily excluded because they were known to be under the care of the HES: 14,734 (8.1%) had previously been screened by the DRSSW at least once and 3,995 (2.1%) had never previously been screened by DRSSW.
Aims This study was to audit the 3,995 patients under care of HES and who have never been screened by DRSSW.
Health Board breakdown Of the 3,995 patients 2,058 (51.5 %) were under the care of four local Health Boards located in South Wales, these were broken down into: • Cardiff and Vale 495 (12.4%) • Abertawe Bro Morgannwg 936 (23.4%) • Cwm Taf 177 (4.4%) • Aneurin Bevan 450 (11.3%)
Results: Of the 2,058 patients audited there were: • 667 (32.4%) without DR Other (NoDR) No DR 14.0% 32.4% • 187 (9.1%) with Background DR RDR (BDR) 44.5% • 915 (44.5%) with referable DR BDR (RDR) 9.1% • 289 (14.0%) were either deceased or categorised as ‘Other’ (e.g. private patients, those with notes not accessible etc.).
Area breakdown results of each Health Board audited so far Total Health Board NoDR BDR RDR Other Audited 495 148 45 277 25 Cardiff and Vale (24.1%) (29.9%) (9.1%) (56.0%) (5.1%) Abertawe Bro 936 282 127 341 186 Morgannwg (45.5%) (30.1%) (13.6%) (36.4%) (19.8%) 177 81 10 51 35 Cwm Taf (8.6%) (45.8%) (5.6%) (28.8%) (19.8%) 450 156 5 246 43 Aneurin Bevan (21.9%) (34.7%) (1.1%) (55.0%) (9.6%)
NoDR Results Mixed co- morbidities, Of those 667 (32.4%) 25.3% persons not under care for DR reasons - 371 (55.6%) had glaucoma, 127 (19.0%) had cataracts and/or age related macular degeneration (ARMD) and Cataracts 169 (25.4%)had a &/or ARMD, variety of other eye Glaucoma, 19.0% conditions which have 55.6% co-morbidities.
Conclusion: The audit of 2,058 (51.5%) of persons with diabetes under the care of HES in four Health Boards in Wales identified: Prevalence of RDR 44.5% and BDR 9.1% 32.4% had NoDR and were not under care for DR but for reasons such as: glaucoma, cataracts and/or age related macular degeneration or other eye conditions with co- morbidities. The difference in rates between the Health Boards for RDR ranged from 29-56% and NoDR from 30-46% and these will be looked at in more detail at a later date.
Discussion: This audit has identified the importance of retaining patients (referred to HES for NoDR) on the DRSSW recall system. This is to ensure that they receive their retinal screening regularly, and thus reduce the risk of sight threatening retinopathy; patients were subsequently recalled for screening as appropriate.
Acknowledgements: Secretarial, IT and Support Ophthalmologists staff Nic Drew Mr Roger McPherson Pamela Roberts Sharon Ragbetli Mr Rob Hill Yvette Tracey Dorian Edwards Mr Geraint Davies Karen Davies Clive Vickery Mr Amit Gaur Lucy Timlin Janet Warren Mr Raghu Ram Tarek Allouni Gemma Francis Betsy Pamplin Ms Sengupta Huu Luu Carla Hiscott Mr Chris Williams Anthea Barnard Alison Owen Mary Morris Pam Rott Janine Collier Suzanne Holloway
Any questions? Thank you email@example.com
Reference: Thomas R.L., Dunstan F.D., Luzio D., Chowdhury S.R., North R.V., Hale S.L., Gibbins R.L., Owens D.R., 2014: Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology 2014; 0 : 1-5
Mor oran E n Eye C e Cen enter er F Facu culty, Res Resident ents, F Fel ellow ows at ARV RVO 201 2019 Wor orkshops Monday, April 29 Res esea earch ch in A Aca cadem emia - Mary Elizabeth Hartnett Mem ember ers-in
89 views • 7 slides
3D Retinal Organoids: New frontiers for regenerative therapies in the eye Harnessing the potential of stem cells Harnessing the potential of stem cells for the treatment of blinding diseases for the treatment of blinding diseases Natalia
525 views • 26 slides
MD/PhD Program Vision: To improve human health by applying the scientific method to prevent and cure disease. Mission To train the next generation of physician scientists prepared to innovate and transform health care and biomedical
541 views • 10 slides
In many countries, blind people are among the poorest of the poor. They have no food, poor sanitation, unsafe drinking water and limited access to health care. About Operation Eyesight + = Donors & Partners Operation Eyesight Mission
581 views • 23 slides
Steven Prawer Bionic Vision Australia, University of Melbourne Victoria The Bionic Eye www.materials.unimelb.edu.au The BVA team z Courtesy of Kumar Ganesan, 2010 10mm Courtesy of Gregg Suaning, 2010 BVAs c ompetitive advantage The
663 views • 20 slides
EMA-HTA Workshop Parallel Advice in Scientific Drug Development The HTA View Professor David Barnett The HTA/Regulatory divide? HTA perspective Regulatory perspective Efficacy Clinical effectiveness Safety Cost effectiveness The same
462 views • 12 slides
Revenio acquires CenterVue 15.4.2019 CEO T Tim imo H Hild ildn CFO Robin P Pulkki kinen 1 Disclaimer Important information This presentation has been prepared by, and the information contained herein (unless otherwise indicated) has
474 views • 29 slides
Corporate Presentation Forward-Looking Statements This presentation has been prepared for informational purposes only and does not purport to be all-inclusive. We have based all forward-looking statements on our current expectations and
551 views • 32 slides
Slide 1 GORING AND WOODCOTE MEDICAL PRACTICE PATIENT PARTICIPATION GROUP (PPG) Open Meeting Looking after Your Eyesight 14 April 2018 Slide 2 Agenda The New Practice Website Julia Beasley Ophthalmology from the GP perspective
991 views • 64 slides
2020-2021 Employee Benefit Presentation 1 WHO, WHAT , WHY ? Who: Introduction ? What are we reviewing today: Open Enrollment Benefit Options ? Why am I on this call: This presentation is to provide an explanation and understanding of
996 views • 23 slides
AI Screening for DR and Chronic Diseases 2018-03-29 Emma Xu, Dr. You Li Impact of Blindness in Elderly Survival Curve for All-cause Mortality in Singapore Malay Impact of Visual Impairment and Eye diseases on Mortality: the Singapore Malay Eye
614 views • 23 slides
Eye Health from A Z Did You Know? 13.5 Vision problems affect nearly million children in the U.S. Students, especially young ones, may not know that what they are experiencing is a vision problem Leads to frustration and worsening
523 views • 10 slides
COMPANY SUMMARY BIO Boston 1x1 meeting PIXIUM VISION ___________ NAME OF THE CEO Khalid ISHAQUE MISSION To create a world of bionic vision for those who have lost their sight, via best in class bionic vision systems that interface the eye
238 views • 3 slides
9/27/17 Objectives Safe Driving for Define the clinical term low vision. Identify common diagnoses that limit driving performance for Individuals with Low individuals with low vision. Describe how driving performance is impacted by visual
594 views • 16 slides
L E ADI NG RE GE NE RAT I VE ME DI CI NE 1 ooking State me nts Cautionar y State me nt Conc e r ning F or war d- L T his pre se ntatio n is inte nde d to pre se nt a summary o f ACT s (ACT , o r Advanc e d Ce
471 views • 24 slides
M IXED - MODEL A NALYSIS OF C OMMON V ARIATION R EVEALS P ATHWAYS E XPLAINING V ARIANCE IN AMD RISK J AKE H ALL | C ASE W ESTERN R ESERVE U NIVERSITY - B USH L AB | IGES 2014 I NTRODUCTION Q UESTION M ETHODS R ESULTS C ONCLUSIONS AMD A ge-related
541 views • 39 slides
Redefining Preventable Blindness - Pharmacological Treatment of Age-Related Vision Loss David T. Shima, PhD Rothes Professor of Translational Vision Research UCL Institute of Ophthalmology The urgency to develop treatments for vision loss:
880 views • 43 slides
Barriers to eye care among participants of a mobile eye clinic Tosha Zaback 1 ,Kousanee Chheda 2 , Rong Wu 3 Mitchell Brinks 1 1 Casey Eye Institute, Oregon Health & Science University, Portland, OR 2 UConn Health, Farmington, CT 3
475 views • 21 slides
A Primer on Precision Medicine: The Legal and Ethical Considerations Faced by Modern Medicines New Frontier By Elizabeth A. Scarola, Carlton Fields Tie National Institutes of Health (NIH) defjnes precision Precision medicine was thrust
529 views • 6 slides
Personalized Medicine: From Promise To Practice Francis S. Collins, M.D., Ph.D. National Human Genome Research Institute Research!America Forum September 19, 2006 We wouldnt think of buying shoes in a single size So why should we be
605 views • 35 slides
plc Developing Innovative Peptides October 2018 Disclaimer This presentation contains certain statements and may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that
225 views • 18 slides
South Shore Clean Cities Northwestern Indiana Regional Planning Commission Environmental Management Policy Committee Meeting September 5, 2019 South Shore Clean Cities About us Past Projects Ongoing Projects Partnerships &
558 views • 53 slides
INNOVATION March 2019 This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers.
570 views • 23 slides
RNIB who are we? RNIB, Action for Blind People, National Talking Newspapers and Magazines and Cardiff, Vales and Valleys, work in partnership to draw on a wide range of skills and resources. Together, we make up the RNIB group of
418 views • 19 slides